An independent researcher has urged for a reassessment of certain medications following a comprehensive analysis by Prescrire International, a French nonprofit. This examination unveiled that Italy expended over €1 billion in 2022 on numerous medicines that may pose more risks than benefits for patients. The organization, consisting primarily of medical professionals and pharmacists, evaluates pharmacological agents authorized in France or the European Union since 2010. In their 2023 analysis, they identified 115 “drugs to avoid.” This revelation is significant given that a year prior, 56 of these drugs were still reimbursed by the Italian health authority, leading to considerable spending, estimated at €1.15 billion. Health economics expert Fabrizio Gianfrate remarked that the figure is remarkably high, emphasizing the need for scrutiny in prescribing practices.
The aim of Prescrire’s initiative is to compare various medications with standard treatment options and assess their adverse effects relative to potential clinical benefits. By reviewing research and patient outcome data, the organization aims to highlight drugs that may provide minimal benefits against their negative side effects. Although inclusion in Prescrire’s list raises questions about certain medications, it does not automatically imply harm to patients. Newer drugs undergo thorough evaluations from the European Union’s medicines regulator before gaining authorization. However, issues may arise post-approval, leading to further reassessment, which Gianfrate noted can serve as a catalyst for reevaluation among healthcare professionals.
The recent analysis, published in JAMA Network Open, indicates that a handful of medications consumed a large proportion of Italy’s spending on drugs deemed to be avoided. Specifically, 15 medicines accounted for 75% of the national expenditure and 80% of patient consumption within the identified category. The compilation included various drug classes, such as five cardiovascular agents, three medications for type 2 diabetes, four antidepressants, two cancer treatment drugs, and a monoclonal antibody designed for osteoporosis. Furthermore, the data revealed that Italians consumed these 56 drugs at a rate of 86.2 doses per 1,000 individuals daily, representing 6.9% of all reimbursed drug consumption.
Despite the apparent need for caution, Gianfrate noted that eliminating these drugs may not result in significant savings. Many patients who discontinue one potentially problematic medication will likely need to transition to alternative drugs, which may possess an even higher cost. Consequently, patients could still become “cost-generators” regardless of whether the initially prescribed problematic medications are avoided. This highlights an ongoing challenge within the healthcare system—how to effectively manage patient care while considering costs and benefits.
The report primarily concentrates on the Italian healthcare landscape; however, it underscores broader implications for patients throughout the European Union. Once pharmaceutical companies obtain regulatory approval through either national authorities or the European Medicines Agency (EMA), decisions surrounding pricing, reimbursement, and prescription practices are disseminated among individual doctors and medical groups. This chain of oversight comprises multiple levels of checks, ensuring that ineffective medications are gradually filtered out of clinical practice. If prescribers identify a lack of efficacy in a medication, they typically refrain from recommending it to their patients, establishing a system designed to prioritize patient welfare.
In conclusion, the findings from Prescrire International’s analysis compel health authorities and professionals to revisit their approaches to medication scrutiny. As the results indicate a troubling trend in drug expenditures, it is essential for the Italian Medicines Agency (AIFA) and other stakeholders to evaluate the risk-benefit profiles of these medications actively. With the independent researcher advocating for necessary re-evaluation efforts, it is crucial for healthcare systems to remain vigilant in ensuring that patients receive the most effective and safe treatments possible. Ultimately, this requires continued dialogue, research, and critical analysis of the medications that populate the market, ensuring that patient safety and efficacy remain at the forefront of healthcare decision-making.
